ArticleFrontiers in immunology2019
BCG Vaccination Induces
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07094711 (Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG in Patients With Mycobacterium Avium Complex Lung Disease), which is not on this map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG in Patients With Mycobacterium Avium Complex Lung Disease (BOOST)
Who cites it
42 citing papers in PubMed, 56 citations in OpenAlex.
- BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA- Indian adults.JCI insight · 2019Trial
- Infantile pulmonary abscess due toFrontiers in pediatrics · 2026Article
- Pathogenicity and virulence ofVirulence · 2025Review
- The Crosstalk BetweenCells · 2025Review
- Immunity AgainstVaccines · 2025Article
- Paediatric cervicofacial lymphadenitis caused by non-tuberculous mycobacteria: nation-wide overview in the period 2000-2020.BMC pediatrics · 2025Article
- Flavin and deazaflavin biosynthesis in mycobacteria: relevance to physiology, implications for drug discovery, MR-1 antigenicity, and vaccine development.Frontiers in immunology · 2025Review
- Assays for AssessingPathogens (Basel, Switzerland) · 2024Article
- Effects of non-tuberculous mycobacteria on BCG vaccine efficacy: A narrative review.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Review
- ELISA-R: an R-based method for robust ELISA data analysis.Frontiers in immunology · 2024Article
- Exploring antibiotic resistance mechanisms inFrontiers in microbiology · 2024Review
- Article
- Review
- Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen.Tuberculosis (Edinburgh, Scotland) · 2023Article
- Bridging the gaps to overcome major hurdles in the development of next-generation tuberculosis vaccines.Frontiers in immunology · 2023Review
- Meeting the challenges of NTM-PD from the perspective of the organism and the disease process: innovations in drug development and delivery.Respiratory research · 2022Review
- Diagnosis and Management of Pulmonary NTM with a Focus onMicroorganisms · 2022Review
- Alternatives to Antibiotics againstAntibiotics (Basel, Switzerland) · 2022Review
- Review
- The Association Between Bacille Calmette-Guérin Vaccination and Nontuberculous Mycobacterial Pulmonary Disease.Journal of Korean medical science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Pulmonary non-tuberculous mycobacterial (NTM) infections particularly caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.